159 related articles for article (PubMed ID: 37595686)
1. Treosulfan-Based Conditioning Regimen In Pediatric Hematopoietic Stem Cell Transplantation: A Retrospective Analysis on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Galán V; Beléndez C; Echecopar C; Estival P; Sissini L; Olivas R; Bueno D; Molina B; Fuentes C; Regueiro A; Benítez I; Plaza M; Margarit A; Rifón J; Pascual A; Palomo P; Urtasun A; Fuster JL; Díaz de Heredia C; Fernández Navarro JM; González-Vicent M; Ruz B; Pérez-Martínez A
Transplant Cell Ther; 2023 Nov; 29(11):702.e1-702.e11. PubMed ID: 37595686
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of treosulfan versus busulfan-based conditioning in pediatric patients.
Olivas-Mazón R; Bueno D; Sisinni L; Mozo Y; Casado-Abad G; Martínez AP
Eur J Haematol; 2022 Nov; 109(5):474-482. PubMed ID: 35810360
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
[TBL] [Abstract][Full Text] [Related]
4. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
5. Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.
Burroughs LM; Nemecek ER; Torgerson TR; Storer BE; Talano JA; Domm J; Giller RH; Shimamura A; Delaney C; Skoda-Smith S; Thakar MS; Baker KS; Rawlings DJ; Englund JA; Flowers ME; Deeg HJ; Storb R; Woolfrey AE
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1996-2003. PubMed ID: 25196857
[TBL] [Abstract][Full Text] [Related]
6. Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens.
Huttunen P; Taskinen M; Vettenranta K
Pediatr Hematol Oncol; 2020 Aug; 37(5):355-364. PubMed ID: 32166994
[TBL] [Abstract][Full Text] [Related]
7. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
Strocchio L; Zecca M; Comoli P; Mina T; Giorgiani G; Giraldi E; Vinti L; Merli P; Regazzi M; Locatelli F
Br J Haematol; 2015 Jun; 169(5):726-36. PubMed ID: 25818248
[TBL] [Abstract][Full Text] [Related]
8. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.
Morillo-Gutierrez B; Beier R; Rao K; Burroughs L; Schulz A; Ewins AM; Gibson B; Sedlacek P; Krol L; Strahm B; Zaidman I; Kalwak K; Talano JA; Woolfrey A; Fraser C; Meyts I; Müller I; Wachowiak J; Bernardo ME; Veys P; Sykora KW; Gennery AR; Slatter M
Blood; 2016 Jul; 128(3):440-8. PubMed ID: 27216217
[TBL] [Abstract][Full Text] [Related]
9. Treosulfan Versus Busulfan-based Conditioning in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis.
Wu W; Xue N; Yang H; Gao P; Guo J; Han D
J Pediatr Hematol Oncol; 2023 Oct; 45(7):370-376. PubMed ID: 37526377
[TBL] [Abstract][Full Text] [Related]
10. Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study.
van der Stoep MYEC; Bertaina A; Moes DJAR; Algeri M; Bredius RGM; Smiers FJW; Berghuis D; Buddingh EP; Mohseny AB; Guchelaar HJ; Locatelli F; Zwaveling J; Lankester AC
Transplant Cell Ther; 2022 Feb; 28(2):99.e1-99.e7. PubMed ID: 34607071
[TBL] [Abstract][Full Text] [Related]
11. Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients: Data from a single center.
Uzay A; Gündoğdu Y; Koşan B; Yetiş T; Kartı SS
Cancer Med; 2024 May; 13(10):e7292. PubMed ID: 38752476
[TBL] [Abstract][Full Text] [Related]
12. Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial.
Peccatori J; Mastaglio S; Giglio F; Greco R; Crocchiolo R; Patriarca F; Forno B; Deola S; Assanelli A; Lupo Stanghellini MT; Marcatti M; Zecca M; Cortelazzo S; Fanin R; Fagioli F; Locatelli F; Ciceri F
Biol Blood Marrow Transplant; 2020 Feb; 26(2):316-322. PubMed ID: 31605823
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
[TBL] [Abstract][Full Text] [Related]
14. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
[TBL] [Abstract][Full Text] [Related]
15. Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia.
Hong KT; Park HJ; Kim BK; An HY; Choi JY; Kang HJ
Transplant Cell Ther; 2022 Apr; 28(4):195.e1-195.e7. PubMed ID: 35021131
[TBL] [Abstract][Full Text] [Related]
16. Outcome of treosulfan-based reduced-toxicity conditioning regimens for HSCT in high-risk patients with primary immune deficiencies.
Haskoloğlu Ş; Köstel Bal S; İslamoğlu C; Altun D; Kendirli T; Doğu EF; İkincioğulları A
Pediatr Transplant; 2018 Nov; 22(7):e13266. PubMed ID: 29992714
[TBL] [Abstract][Full Text] [Related]
17. [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].
Hu SS; Wu YB; Zhu PP; Shi JM; Yu J; Zhao YM; Lai XY; Liu LZ; Fu HR; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):992-1002. PubMed ID: 36709104
[No Abstract] [Full Text] [Related]
18. Haploidentical transplantation in pediatric non-malignant diseases: A retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation (GETH).
Torres Canizales J; Ferreras C; Pascual A; Alonso L; Regueiro A; Plaza M; Pérez Hurtado JM; Benito A; Couselo JM; Fuster JL; Díaz-Almirón M; Bueno D; Mozo Y; Gómez López A; Vicario JL; Balas A; Sisinni L; Díaz de Heredia C; Pérez-Martínez A
Eur J Haematol; 2021 Feb; 106(2):196-204. PubMed ID: 33084101
[TBL] [Abstract][Full Text] [Related]
19. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two cytoreductive regimens for αβ-T-cell-depleted haploidentical HSCT in pediatric malignancies: Improved engraftment and outcome with TBI-based regimen.
Jacoby E; Varda-Bloom N; Goldstein G; Hutt D; Churi C; Vernitsky H; Toren A; Bielorai B
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28988422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
